{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rosacea/prescribing-information/topical-treatments/","result":{"pageContext":{"chapter":{"id":"e6e7bc13-b6bd-5b5e-b337-196c3291ee63","slug":"topical-treatments","fullItemName":"Topical treatments","depth":2,"htmlHeader":"<!-- begin field ff1bec29-d7e0-47fd-9018-ddf43b8984e7 --><h2>Topical treatments</h2><!-- end field ff1bec29-d7e0-47fd-9018-ddf43b8984e7 -->","summary":"","htmlStringContent":"<!-- begin item c07ae6ef-0e2e-4b69-82d5-3cd1b82cf755 --><!-- end item c07ae6ef-0e2e-4b69-82d5-3cd1b82cf755 -->","topic":{"id":"907deb55-501c-50b0-9c07-5956c70cf201","topicId":"d6855039-5025-454d-b195-d4b0a3763978","topicName":"Rosacea ","slug":"rosacea","lastRevised":"Last revised in January 2021","chapters":[{"id":"a3d8bb8f-cf98-5320-abe8-71c7b0c3d604","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a9c3b514-8e94-52d5-8de7-2caedcdd8ed3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"efe24f29-88ad-5507-b4b5-ec00c54a404d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"10634254-4474-5303-9337-e3682fd14514","slug":"changes","fullItemName":"Changes"},{"id":"1ad5ada5-1ed7-5223-b60c-122b20127e1e","slug":"update","fullItemName":"Update"}]},{"id":"832a95da-0571-5031-b437-3cc5568bc7fa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"59d41997-63c3-57d4-8c29-c4655d090e7a","slug":"goals","fullItemName":"Goals"},{"id":"2c3bc0a5-be4b-5a98-a5d8-02e7cb85b9cb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f8c34a65-7879-5a21-87df-68739ba5d1f3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9f050a9b-10be-5d79-b662-0099ac611890","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9fcdbb11-1f96-5ae9-aeec-617a9da55e12","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"538579d3-7620-5145-a70f-022ec13226ae","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0b606da-7836-5c33-8390-23a6dad9e7bd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ed198aaf-1444-5590-ab74-c9fdff996b5e","slug":"definition","fullItemName":"Definition"},{"id":"df406671-3834-580f-836a-3c2428245359","slug":"prevalence","fullItemName":"Prevalence"},{"id":"be28c459-5653-506e-937c-5c4d2f7ceecd","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"bc98e144-7d7d-5fa2-97ad-7c1bd8526ca0","slug":"complications","fullItemName":"Complications"},{"id":"1a5cbcf6-2870-5a82-a207-8c8888f907d2","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"d654b61f-b47e-5123-b965-f806f0eb2e6d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"bd6d5455-d63e-5507-8bdd-028b338047cc","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"30d3265f-84ec-5ac7-a410-bc11cd078ac9","slug":"assessment","fullItemName":"Assessment"},{"id":"e111154d-c82a-5292-b201-f4a12a8a4d17","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"e753e991-54fe-5ab5-96d2-124372f1292f","fullItemName":"Management","slug":"management","subChapters":[{"id":"0e7b3ebf-33f5-5b51-a9ab-81c8dda1332f","slug":"rosacea","fullItemName":"Scenario: Rosacea"}]},{"id":"602c95a0-f64e-593e-85c4-798ea728733b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e6e7bc13-b6bd-5b5e-b337-196c3291ee63","slug":"topical-treatments","fullItemName":"Topical treatments"},{"id":"c53198f5-f60b-5fb6-8767-9f9a275329f5","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"}]},{"id":"0db34d3f-c02f-5b8f-8498-90541139bc2a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ca47aba9-e0da-5e0a-a1a2-46bfab6fe609","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5c0a0103-4ed2-586f-8fbd-aaf6fe82f548","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"84966474-462f-592c-b43d-474d1ca89d52","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2d8252-c981-52ba-9faf-d9e9450efe7c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f5e586ed-912a-51ab-b246-3a6f6c67e2d1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"a60f4af9-1a6a-5a71-9310-2b3fe7d0cb92","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40a50d91-c85e-5b2c-b283-ca2a9f30c6f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"602c95a0-f64e-593e-85c4-798ea728733b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"0e70174d-1011-5fc5-8584-adedc90b0ade","slug":"brimonidine","fullItemName":"Brimonidine","depth":3,"htmlHeader":"<!-- begin field b876dfce-26e9-4353-975d-822b40a29064 --><h3>Brimonidine</h3><!-- end field b876dfce-26e9-4353-975d-822b40a29064 -->","summary":"","htmlStringContent":"<!-- begin item 78b3dd35-e836-4966-a695-ed63aa0e7b62 --><!-- begin field 787b10f3-a44e-403e-a9a4-c201c9c1948b --><h4>Contraindications and cautions</h4><ul><li><strong>Avoid the use of topical brimonidine in people who:</strong><ul><li>Have cerebral insufficiency.</li><li>Have coronary insufficiency or severe cardiovascular disease.</li><li>Have depression.</li><li>Have postural hypotension.</li><li>Have Raynaud's syndrome.</li><li>Have thromboangiitis obliterans.</li><li>Have hepatic or renal impairment.</li><li>Are pregnant or breastfeeding — manufacturer advises to avoid, but limited information available.</li></ul></li><li><strong>Avoid contact of brimonidine gel with</strong> the eyes, mouth, mucous membranes. Avoid application to irritated or damaged skin to minimize the risk of systemic absorption.</li><li><strong>Apply other topical preparations</strong> (including cosmetics) only after brimonidine gel has dried on the skin.</li></ul><h4>Adverse effects</h4><ul><li><strong>Possible adverse effects of topical brimonidine include:</strong><ul><li>Dizziness, dry mouth, headache, skin reactions, flushing (common).</li><li>Angio-oedema, eyelid oedema, nasal congestion, paraesthesia, cold peripheries (uncommon).</li><li>Systemic cardiovascular effects, such as dizziness (common), hypotension, bradycardia (rare).</li><li>Possible exacerbation of rosacea symptoms (common) — treatment should be initiated with a small amount of gel (less than the maximum dose) for at least 1 week, then increased gradually, based on tolerability and response. The maximum daily dose (1 g of gel per day) should not be exceeded, and the person should stop treatment and seek medical advice if symptoms worsen during treatment.</li></ul></li></ul><h4>Drug interactions</h4><ul><li>There are no reported major drug interactions with topical brimonidine.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">MHRA, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">MHRA, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 787b10f3-a44e-403e-a9a4-c201c9c1948b --><!-- end item 78b3dd35-e836-4966-a695-ed63aa0e7b62 -->","subChapters":[]},{"id":"46079500-b0e1-5f9f-acb1-fef74fee17a5","slug":"ivermectin","fullItemName":"Ivermectin","depth":3,"htmlHeader":"<!-- begin field fb42d84e-d1a1-46d1-860f-abc9016253ad --><h3>Ivermectin</h3><!-- end field fb42d84e-d1a1-46d1-860f-abc9016253ad -->","summary":"","htmlStringContent":"<!-- begin item 1302fc9e-7c6b-4c65-9105-abc901625353 --><!-- begin field 450fb395-848e-4a33-a255-abc9016253ad --><h4>Contraindications and cautions</h4><ul><li><strong>Prescribe topical ivermectin with caution to people:</strong><ul><li>With severe hepatic impairment.</li><li>Who are pregnant or breastfeeding — manufacturer advises to avoid, but limited information available.</li></ul></li></ul><h4>Adverse effects</h4><ul><li>Common possible adverse effects are skin reactions.</li></ul><h4>Drug interactions</h4><ul><li>As systemic absorption can follow topical application, there is a potential risk that topical ivermectin can increase the anticoagulant effect of warfarin.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 450fb395-848e-4a33-a255-abc9016253ad --><!-- end item 1302fc9e-7c6b-4c65-9105-abc901625353 -->","subChapters":[]},{"id":"7baef991-4136-51e7-bd90-f990b653d607","slug":"azelaic-acid","fullItemName":"Azelaic acid","depth":3,"htmlHeader":"<!-- begin field a0164561-43b1-4379-8818-be3c50b480bb --><h3>Azelaic acid</h3><!-- end field a0164561-43b1-4379-8818-be3c50b480bb -->","summary":"","htmlStringContent":"<!-- begin item ed2e07c0-c9f3-4339-be42-c0c5be3d7aec --><!-- begin field 6e0e2a5f-0b4a-4ba3-9820-988d470e163b --><h4>Contraindications and cautions</h4><ul><li>Avoid contact of topical azelaic acid with the eyes, mouth, and mucous membranes.</li></ul><h4>Adverse effects</h4><ul><li>Possible adverse effects of topical azelaic acid include:<ul><li>Skin reactions (uncommon).</li><li>Exacerbation of asthma (rare).</li><li>Cheilitis (rare).</li></ul></li></ul><h4>Drug interactions</h4><ul><li>There are no reported drug interactions with topical azelaic acid.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 6e0e2a5f-0b4a-4ba3-9820-988d470e163b --><!-- end item ed2e07c0-c9f3-4339-be42-c0c5be3d7aec -->","subChapters":[]},{"id":"843fe462-2d3c-5aff-a9b5-fd2bfe43171f","slug":"metronidazole","fullItemName":"Metronidazole","depth":3,"htmlHeader":"<!-- begin field 55f01abd-1ac1-4391-8908-abc9016209a5 --><h3>Metronidazole</h3><!-- end field 55f01abd-1ac1-4391-8908-abc9016209a5 -->","summary":"","htmlStringContent":"<!-- begin item dbec2d62-c26d-4f86-8ccd-abc9016208fa --><!-- begin field abb5cb1d-601c-4313-99ac-abc9016209a5 --><h4>Contraindications and cautions</h4><ul><li>Avoid exposure to strong sunlight or ultraviolet light with topical use.</li><li>Avoid contact with the eyes, mouth, and mucous membranes.</li></ul><h4>Adverse effects</h4><ul><li>Common possible adverse effects are skin reactions.</li><li>Severe bullous skin reactions, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or acute generalised exanthematous pustulosis (AGEP), have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul><h4>Drug interactions</h4><ul><li>As systemic absorption can follow topical application, there is a potential risk that topical metronidazole may:<ul><li>Increase the concentration of lithium.</li><li>Increase the anticoagulant effect of warfarin.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rosacea/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field abb5cb1d-601c-4313-99ac-abc9016209a5 --><!-- end item dbec2d62-c26d-4f86-8ccd-abc9016208fa -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}